Figure 1.

Deletion of Hif-1α Leads to a Faster Progression of AML after Chemotherapy Treatment

(A–H) Experimental design for the generation of leukemic clones, deletion of Hif-1α, and applied chemotherapy protocol (A). At day 28 after transplantation, mice were sacrificed and disease evolution was examined according to different parameters: total white blood cell count in PB (B), myeloid cells (Gr1⁺-CD11b⁺) (C), GFP⁺ cells in PB, BM, and spleen (D and E), splenomegaly (F), GFP⁺ c-Kit⁺ cells in BM and spleen (G), and GFP⁺ Lin^– c-Kit⁺ in BM and spleen (H). Results are from 1 of 2 experiments and depict results from 4 mice per group (3 for wild-type control mice). Plots represent mean ± SEM. ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.01. AraC, cytarabine; Dox, doxorubicin; CTX, chemotherapy; BM, bone marrow; Ctrl, control.

See also Figures S1 and S2.